Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study

► Analysis of a randomized trial in ovarian cancer, neither erythropoietin nor granulocyte colony stimulating agents had a survival impact. ► Adjustments were made for factors known to impact survival; stage, residual tumor, and performance status. ► Landmark analysis was employed since patients may have received cytokine at any time during chemotherapy.